Thyroid Cancer Trial, Recruiting NCT07138716 Sponsor: Luo Yaping Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT07138716
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any age, whether male or female, may be considered
  • People who have been diagnosed with, or are suspected to have, a type of thyroid cancer called medullary thyroid carcinoma (MTC) — confirmed through a biopsy, elevated blood markers alongside a thyroid nodule, or a family history suggesting a hereditary condition (such as MEN2 syndrome)
  • People with certain other confirmed cancers (such as some neuroendocrine tumors, or stomach or ovarian cancers) that test positive for a specific protein called CCK-2R (confirm with trial site)
  • People who are expected to live for at least 12 weeks at the time of joining
  • People who are willing to use effective birth control during the study, if this applies to them
  • People who are willing to sign a consent form and attend follow-up appointments as required

Who may not be able to join:

  • People with serious liver or kidney problems, as shown by certain abnormal blood test results (confirm with trial site for specific values)
  • People who are currently pregnant, breastfeeding, or planning to become pregnant during the study
  • People who are unable to lie still during a PET/CT scan — for example, due to severe claustrophobia
  • People with other health conditions that the trial doctor believes could make participation unsafe (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yaping LUO, Peking Union Medical College Hospital

Phone: 86-010-69154716

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Luo Yaping
Registry
ClinicalTrials.gov
Start date
10 May 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

diagnostic performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov